---
title: "Aptose Reports Q1 2026 Loss of $7.6M, Cash $4.1M as Acquisition by Hanmi Pending"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286320355.md"
description: "Aptose reported a Q1 2026 net loss of $7.6 million, up from a $5.5 million loss in Q1 2025. Total operating expenses were $7.2 million, with cash and restricted cash at $4.1 million. The company relies on advances from Hanmi for operations pending acquisition closure, which is delayed due to regulatory approvals. Clinical progress for tuspetinib continues, with data presentation scheduled for EHA 2026. Aptose returned luxeptinib license rights to CGI and is implementing cost reductions to extend its financial runway."
datetime: "2026-05-13T21:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286320355.md)
  - [en](https://longbridge.com/en/news/286320355.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286320355.md)
---

# Aptose Reports Q1 2026 Loss of $7.6M, Cash $4.1M as Acquisition by Hanmi Pending

Aptose reported a net loss of $7.6 million for the quarter ended March 31, 2026, compared with a $5.5 million loss in Q1 2025. Total operating expenses were $7.2 million and cash and restricted cash totaled $4.1 million as of March 31, 2026; the company said it relies on advances from Hanmi to fund operations pending closing of an acquisition. Aptose also noted continued clinical progress for tuspetinib with an oral data presentation at EHA 2026 and returned luxeptinib license rights to CGI.

**Financial Highlights**

-   Net loss: $(7.6) million for the three months ended March 31, 2026, versus $(5.5) million in Q1 2025.
-   Total operating expenses: $7.182 million for Q1 2026.
-   Research and development expense: $3.621 million for Q1 2026 (including $2.880 million program costs for tuspetinib).
-   General and administrative expense: $3.561 million for Q1 2026.
-   Cash and restricted cash: $4.105 million as of March 31, 2026; working capital deficit $(5.084) million and shareholders’ deficit $(34.672) million.

**Business Highlights**

-   TUSCANY trial progress: Updated TUS+VEN+AZA triplet data (including 80 mg, 120 mg and new 160 mg dose cohorts) selected for oral presentation at EHA 2026 on June 14, 2026, with updated safety, CR and MRD data and longer follow-up.
-   Acquisition update: Closing of the arrangement with Hanmi Pharmaceutical has been delayed due to pending Korean regulatory approvals; parties continue to target closing in May and expect reviews will not prevent closing.
-   License return: Aptose returned the exclusive license rights to CGI for CG-806 (luxeptinib) under a Termination of License Agreement.
-   Operational funding: Company states it does not have sufficient cash to fund operations independently and is relying on advances from Hanmi while implementing cost reduction efforts to extend runway.
-   Share capital details: As of May 8, 2026, 2,552,429 common shares issued and outstanding, plus 37,083 issuable on options and 1,139,085 issuable on warrants.

Original SEC Filing: Aptose Biosciences Inc. \[ APTOF \] - 8-K - May. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [APTO.US](https://longbridge.com/en/quote/APTO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [APTOF.US](https://longbridge.com/en/quote/APTOF.US.md)
- [GIB.US](https://longbridge.com/en/quote/GIB.US.md)

## Related News & Research

- [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md)
- [Has the bull market shifted to biotech stocks?](https://longbridge.com/en/news/293077044.md)
- [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md)
- [Biotech experts want FDA drug reviews based on science, not politics](https://longbridge.com/en/news/293453841.md)
- [3 healthcare ETFs to own in a choppy stock market](https://longbridge.com/en/news/291834343.md)